Is mTORC1 one pathway or several separable outputs — and which of them carries ageing?

Framing gap · evidence stands at: Lifespan in mice · Atlas ID F2

The gap

Most of the argument is about how hard to press the brake, and recently about which of the two brakes to press. Hardly anyone asks which of the things the brake controls actually needs slowing. And those things do come apart: in muscle, fixing one downstream branch rescues the problem while removing another does nothing.

Technical framing: The field asks how much mTORC1 to inhibit, and lately which complex to spare. It rarely asks which of mTORC1's outputs needs inhibiting at all. Yet the outputs behave differently: the 4E-BP1 arm and the S6K1 arm separate in muscle, where activating 4E-BP1 rescues a sarcopenia model and deleting S6K1 does not; bi-steric inhibitors reactivate 4E-BP1 where rapalogs cannot; and lysosomal localisation and mTORC1 activity can be uncoupled, so different substrates need not move together.

What changed

Substrate selectivity has moved from a curiosity to a stated paradigm shift in the 2026 review literature, on the back of results showing that where mTORC1 sits and which substrates it reaches are not the same variable as how active it is. On the therapeutic side, bi-steric inhibitors are the first tool that changes the output profile rather than only the output amount (Mahauad-Fernandez, Cell Chem Biol 2025, PMID 40803322), and they have now been through a human phase 1 (Schram, Clin Cancer Res 2025, PMID 41056387).

What is still open

Which outputs are required for geroprotection. No lifespan experiment has compared mTORC1 outputs at matched mTORC1 activity. Single-output genetics exists - S6K1 deletion extends female mouse lifespan (SEL2009) and 4E-BP mediates dietary-restriction lifespan extension in flies (ZID2009) - but there is no 4E-BP1-arm-only ITP cohort, no S6K1-arm-only cohort at matched mTORC1 activity, and no bi-steric lifespan data in any species.

How it could be tested

An ITP-style lifespan protocol comparing rapamycin against a bi-steric at doses matched for total mTORC1 inhibition but differing in 4E-BP1 engagement. If lifespan tracks 4E-BP1 dephosphorylation rather than overall mTORC1 suppression, the target is an output, not the complex. Genetic arm: 4E-BP1 and S6K1 manipulations on a common background with the same endpoints.

Why it matters

It would change what a geroprotective drug is supposed to do. Sparing mTORC2 is a question about avoiding harm; choosing outputs is a question about where the benefit lives, and it may explain why deeper inhibition is not reliably better.

Bears on these open questions

• mTORC1-selective (mTORC2-sparing) dosing captures longevity without insulin resistance
• Muscle-sparing, pulsed mTORC1 inhibition
• Is autophagy actually REQUIRED for the mammalian lifespan benefit?

← All frontier questions · Open questions